Figure 6. Behavioral consequences of PhLP1 elimination in striatal neurons.
(A) Pdcl cKO mice display normal basal locomotion and habituation to a novel environment. (B) Total distance traveled in 2 hr in the open field chamber. (C) Average velocity in the open field chamber. (D) Pdcl cKO mice exhibit severe deficits in motor learning behavior in rotarod test. There were statistically significant differences between genotype as determined by Two-way ANOVA (F[1, 153] = 63.518, p<0.001). *p<0.05, **p<0.01, ***p<0.001, post hoc Tukey’s test, n = 9 and 10 for control mice and Pdcl cKO mice, respectively. (E) Increased grip strength of the forelimbs in Pdcl cKO mice. *p<0.05, Student’s t-test, n = 8 mice for each genotype. (F) Increased acoustic startle response of Pdcl cKO as measured by Vmax in response to 120 dB white noise bursts. (G) Normal locomotor response to D1R agonist SKF 38,393 (SKF, 50 mg/kg, i.p.) in Pdcl cKOcompared to control mice. Mice were injected with vehicle or SKF 38,393 (SKF, 50 mg/kg, i.p.) and immediately put in open field chambers. The locomotion was recorded for 1 hr. Data were analyzed by Two-way ANOVA (treatment F[1, 28]=96.068, p<0.001, genotype F[1, 28] = 2.679, p = 0.113). *p<0.01 post hoc Tukey’s test compared to the vehicle control of the same genotype. n=8 mice per each genotype. (H) Blunted response to A2AR antagonist SCH58261 (SCH, 3 mg/kg, i.p.) treatment. Data were analyzed by Two-way ANOVA (treatment F(1, 28) = 42.819, p<0.001, genotype F(1, 28) = 20.181, p<0.001). *p<0.01 post hoc Tukey’s test compared to the vehicle control of the same genotype, #p<0.05 post hoc Tukey’s test in comparison between genotypes in response to SCH 58261. n = 8 mice per each genotype. (I) Reduced catalepsy in response to D2R antagonist haloperidol (2 mg/kg, i.p.) in Pdcl cKO mice. Catalepsy was measured in the bar test 1 hr after haloperidol (2 mg/kg, i.p.) administration. *p<0.05, Student’s t-test. n = 8 mice per each genotype.